HUP0003292A1 - Lipofil vegyületeket tartalmazó gyógyászati készítmények önemulgeáló formában - Google Patents

Lipofil vegyületeket tartalmazó gyógyászati készítmények önemulgeáló formában

Info

Publication number
HUP0003292A1
HUP0003292A1 HU0003292A HUP0003292A HUP0003292A1 HU P0003292 A1 HUP0003292 A1 HU P0003292A1 HU 0003292 A HU0003292 A HU 0003292A HU P0003292 A HUP0003292 A HU P0003292A HU P0003292 A1 HUP0003292 A1 HU P0003292A1
Authority
HU
Hungary
Prior art keywords
self
diglyceride
approx
pharmaceutically acceptable
monoglyceride
Prior art date
Application number
HU0003292A
Other languages
English (en)
Inventor
Ping Gao
Walter Morozowich
Original Assignee
Pharmacia & Upjohn Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co. filed Critical Pharmacia & Upjohn Co.
Publication of HUP0003292A1 publication Critical patent/HUP0003292A1/hu
Publication of HUP0003292A3 publication Critical patent/HUP0003292A3/hu
Publication of HU225160B1 publication Critical patent/HU225160B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

A találmány tárgya egy speciális olajos fázis alkalmazásán alapuló újgyógyászati készítmény; mely hatóanyagként (I), (II), (III) vagy (IV)általános képletű piranonszármazékot tartalmaz; tartalmaz, továbbá egydiglicerid/monoglicerid elegyet, melyben a diglicerid:monogliceridarány (kb. 9 : 1)-(kb. 6 : 4), mely digliceridek és monogliceridek aglicerin egyszeresen vagy kétszeresen telítetlen zsírsavakkal alkotottészterei 16-22 szénatomos szénlánccal; továbbá egy vagy többgyógyászatilag elfogadható oldószert és egy vagy több gyógyászatilagelfogadható felületaktív anyagot. A készítmény önemulgeáló formábanvan, mely a lipofil piranonszármazékok vagy koncentrációját ésnagymértékű orális biológiai hozzáférhetőségét biztosítja. Akészítmények humán retrovírussal fertőzött betegek kezelésérealkalmazhatók. Ó
HU0003292A 1997-07-29 1998-07-27 Self-emulsifying formulation for lipophilic compounds HU225160B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5407897P 1997-07-29 1997-07-29
PCT/US1998/014816 WO1999006043A1 (en) 1997-07-29 1998-07-27 Self-emulsifying formulation for lipophilic compounds

Publications (3)

Publication Number Publication Date
HUP0003292A1 true HUP0003292A1 (hu) 2002-01-28
HUP0003292A3 HUP0003292A3 (en) 2002-02-28
HU225160B1 HU225160B1 (en) 2006-07-28

Family

ID=21988649

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003292A HU225160B1 (en) 1997-07-29 1998-07-27 Self-emulsifying formulation for lipophilic compounds

Country Status (23)

Country Link
US (2) US6531139B1 (hu)
EP (1) EP0999838B1 (hu)
JP (1) JP5005847B2 (hu)
KR (1) KR100509130B1 (hu)
CN (1) CN1113650C (hu)
AT (1) ATE215370T1 (hu)
AU (1) AU728695B2 (hu)
BR (1) BR9810866B1 (hu)
CA (1) CA2294032A1 (hu)
DE (1) DE69804624T2 (hu)
DK (1) DK0999838T3 (hu)
ES (1) ES2174462T3 (hu)
FI (1) FI20000171A (hu)
HK (1) HK1028877A1 (hu)
HU (1) HU225160B1 (hu)
NO (1) NO323773B1 (hu)
NZ (1) NZ502567A (hu)
PL (1) PL192080B1 (hu)
PT (1) PT999838E (hu)
RU (1) RU2203648C2 (hu)
SI (1) SI0999838T1 (hu)
SK (1) SK284579B6 (hu)
WO (1) WO1999006043A1 (hu)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9811058A (pt) * 1997-07-29 2000-09-05 Upjohn Co Formulação auto-emulsificante para compostos lipofìlicos
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
ES2234582T3 (es) * 1999-03-31 2005-07-01 PHARMACIA & UPJOHN COMPANY LLC Emulsiones farmaceuticas para inhibidores de proteasas retrovirales.
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
FR2805761B1 (fr) * 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
US6623765B1 (en) * 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
EE200300201A (et) * 2000-10-31 2003-08-15 Boehringer Ingelheim Pharmaceuticals, Inc. Püranoonsete proteaasi inhibiitorite iseemulgeeruva kompositsiooni oraalne doos
KR20020066778A (ko) * 2001-02-13 2002-08-21 한국과학기술연구원 체내 난흡수 물질의 흡수촉진용 조성물과 제형 및 그의제조방법
US6680470B1 (en) * 2001-11-14 2004-01-20 Dicon Fiberoptics, Inc. Interleaver with thermal and chromatic dispersion compensation
EP1461056A4 (en) * 2001-11-26 2006-01-25 Supergen Inc PROCESS FOR THE PREPARATION AND USE OF POLYOXYETHYLATED CICRIC OIL IN PHARMACEUTICAL COMPOSITIONS
US20030191093A1 (en) * 2001-12-03 2003-10-09 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20030199584A1 (en) * 2002-04-11 2003-10-23 Ahluwalia Gurpreet S. Reduction of hair growth
US7182950B2 (en) * 2002-06-12 2007-02-27 Nutralease Ltd. Nano-sized self-assembled liquid dilutable vehicles
KR100533458B1 (ko) * 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US20060251685A1 (en) * 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
GB0402679D0 (en) * 2004-02-06 2004-03-10 Novartis Ag Organic compounds
KR20050081092A (ko) * 2004-02-12 2005-08-18 한국과학기술연구원 생체적합성 친수성 고분자를 포함하는 콜로이드계 조성물,제형 및 이들의 제조 방법
EP1966192B1 (en) * 2005-12-01 2012-10-17 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2008058234A2 (en) * 2006-11-08 2008-05-15 Memory Pharmaceuticals Corporation Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility
BRPI0808354A2 (pt) * 2007-03-09 2014-07-29 Novartis Ag Sais de 3-(1h-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4 -il]-pirrola-2,5-diona
JP2011504162A (ja) * 2007-05-23 2011-02-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 経口投与用チプラナビルの自己乳化型製剤
HU227873B1 (hu) * 2007-06-18 2012-05-29 Biogreen As Növényicsíra-alapú emulziók, eljárás az elõállításukra és alkalmazásuk
AU2008269179A1 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without Tween 80
EP2249839A4 (en) 2008-03-07 2013-10-16 Chemwerth FULVESTRANTFORMULIERUNGEN
EP2257220B1 (en) * 2008-03-13 2017-06-14 Liebel-Flarsheim Company LLC Multi-function, foot-activated controller for imaging system
AU2009319167A1 (en) * 2008-11-28 2010-06-03 Lectio Pharmaentwicklungs-Und Verwertungs Gmbh Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
KR101685941B1 (ko) 2009-07-07 2016-12-13 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스 프로테아제 억제제를 위한 약제학적 조성물
WO2011047259A1 (en) 2009-10-16 2011-04-21 Glaxosmithkline Llc Compositions
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
EP2566474B1 (en) 2010-05-03 2017-11-15 Teikoku Pharma USA, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2012010942A2 (en) * 2010-07-22 2012-01-26 Lupin Limited Novel pharmaceutical composition(s) of hiv protease inhibitor(s)
WO2012039768A2 (en) * 2010-09-24 2012-03-29 Texas Southern University Itraconazole formulations
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US10711238B2 (en) 2012-10-02 2020-07-14 Repligen Corporation Method for proliferation of cells within a bioreactor using a disposable pumphead and filter assembly
WO2014128564A2 (en) 2013-02-21 2014-08-28 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
CA2974495C (en) * 2015-01-21 2023-05-23 Mochida Pharmaceutical Co., Ltd. .omega.-3 fatty acid self-emulsifying composition
CN107847437B (zh) 2015-05-28 2024-03-26 瑞迪博士实验室有限公司 用于治疗疼痛的塞来昔布口服组合物
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
TWI676824B (zh) 2019-01-09 2019-11-11 友達光電股份有限公司 顯示裝置及顯示方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230702A (en) 1978-01-09 1980-10-28 Kali-Chemie Pharma Gmbh Readily enterally absorbable pharmaceutical compositions of per se poorly enterally absorbable pharmacologically active agents
JPS5618914A (en) * 1979-07-25 1981-02-23 Eisai Co Ltd Ubidecarenone composition having good absorbability
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
JPH0629180B2 (ja) * 1986-06-16 1994-04-20 エーザイ株式会社 吸収性の改良されたメナテトレノン含有組成物
DE3629386A1 (de) * 1986-08-29 1988-03-03 Scherer Gmbh R P Gelatinekapseln und verfahren zu ihrer herstellung
ES2042527T3 (es) 1986-11-14 1993-12-16 Theratech Inc Un metodo para preparar una composicion farmaceutica aumentadora de la penetracion para la aplicacion topica.
JP2632010B2 (ja) * 1988-01-29 1997-07-16 三共株式会社 シクロスポリン製剤
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
IL102236A0 (en) * 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
EP0589843B1 (en) * 1992-09-25 2001-11-28 Novartis AG Pharmaceutical compositions containing cyclosporins
WO1994008603A1 (en) * 1992-10-16 1994-04-28 Smithkline Beecham Corporation Compositions
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
PT831826E (pt) 1995-06-06 2003-02-28 Hoffmann La Roche Composicao farmaceutica que inclui um inibidor de proteinase e um monoglicerideo
DE19537012A1 (de) * 1995-10-04 1997-04-10 Dietl Hans Cyclosporin(e) enhaltende pharmazeutische Zubereitung zur oralen Applikation und Verfahren zu ihrer Herstellung
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
BR9811058A (pt) * 1997-07-29 2000-09-05 Upjohn Co Formulação auto-emulsificante para compostos lipofìlicos

Also Published As

Publication number Publication date
BR9810866B1 (pt) 2010-07-13
DE69804624T2 (de) 2002-09-19
SK182000A3 (en) 2000-12-11
BR9810866A (pt) 2000-09-26
CN1113650C (zh) 2003-07-09
EP0999838A1 (en) 2000-05-17
AU728695B2 (en) 2001-01-18
AU8573798A (en) 1999-02-22
CA2294032A1 (en) 1999-02-11
DE69804624D1 (de) 2002-05-08
JP2002510329A (ja) 2002-04-02
US6531139B1 (en) 2003-03-11
DK0999838T3 (da) 2002-07-08
PL338334A1 (en) 2000-10-23
NO20000465D0 (no) 2000-01-28
HU225160B1 (en) 2006-07-28
RU2203648C2 (ru) 2003-05-10
ATE215370T1 (de) 2002-04-15
EP0999838B1 (en) 2002-04-03
NO20000465L (no) 2000-03-28
JP5005847B2 (ja) 2012-08-22
ES2174462T3 (es) 2002-11-01
PT999838E (pt) 2002-07-31
PL192080B1 (pl) 2006-08-31
SK284579B6 (sk) 2005-07-01
FI20000171A (fi) 2000-01-28
HK1028877A1 (en) 2001-03-09
KR100509130B1 (ko) 2005-08-18
SI0999838T1 (en) 2002-08-31
KR20010022364A (ko) 2001-03-15
NO323773B1 (no) 2007-07-02
HUP0003292A3 (en) 2002-02-28
NZ502567A (en) 2002-03-28
CN1261797A (zh) 2000-08-02
US6121313A (en) 2000-09-19
WO1999006043A1 (en) 1999-02-11

Similar Documents

Publication Publication Date Title
HUP0003292A1 (hu) Lipofil vegyületeket tartalmazó gyógyászati készítmények önemulgeáló formában
CA2294031A1 (en) SELF-EMULSIFYING FORMULATION FOR LIPOPHILIC COMPOUNDS
DK1173153T3 (da) Orale farmaceutiske præparater, som indeholder langkædede triglycerider og lipofile overfladeaktive midler
ES2185179T3 (es) Preparacion de composiciones farmaceuticas.
HUP0400566A2 (hu) Mátrixon diszpergált hatóanyagot tartalmazó gyógyászati készítmény
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
HUP0500843A2 (hu) Fokozott biológiai hasznosulású, szájon át hatásos taxánszármazékokat tartalmazó gyógyszerkészítmények
NO153637C (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat som er egnet for transdermal administrering av virkestoffer.
NO863636L (no) Fremgangsmaate for fremstilling av transdermalt resorberbare preparater av arylpropionsyrederivater.
HUP0002440A2 (hu) Savas lipofil vegyületeket tartalmazó gyógyászati készítmény ön-emulgeáló formában
DK1341524T3 (da) Farmaceutisk præparat i form af en pasta omfattende en syre-labil aktiv bestanddel
KR100352088B1 (ko) 미녹시딜 함유 외용 에멀젼 조성물
DE3669106D1 (de) Pharmazeutische zusammensetzungen mit gehalt an flavanolignanen und phospholipiden als wirkstoffe.
KR970705553A (ko) 디히드로벤조푸란, 및 항염증 약물로서 유용한 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents)
ATE258427T1 (de) Pharmazeutische formulierungen enthaltend entzündungshemmende wirkstoffe und deren verwendung
ATE242626T1 (de) Wasserlösliche pharmazeutische darreichungsform, ausgenommen brause-formen, welche nicht- steroidale antientzündliche wirkstoffe enthält
ES2234582T3 (es) Emulsiones farmaceuticas para inhibidores de proteasas retrovirales.
Chandra et al. Clinical pharmacology studies with Centchroman
ATE301453T1 (de) Injizierbare arzneiformulierungen von partricin derivaten
ATE140623T1 (de) Pharmazeutische zusammensetzungen für die orale, kutane und intravaginale anwendung in form eines schaums

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, DE

Free format text: FORMER OWNER(S): PHARMACIA & UPJOHN CO., US

MM4A Lapse of definitive patent protection due to non-payment of fees